PRediciton of IMmunogenic Epitopes (PRIME2.1)
Write your peptide sequences (8- to 14-mers) in the box below (either one peptide per line or in fasta format, only capital letters):
|
|
Example of peptide sequences.
PRIME is a class I immunogenicity predictor combining affinity predictions to HLA-I
molecules together with TCR recognition propensity. It can be
run with any HLA-I alleles from this list. PRIME2.1
is running on this web interface.
PRIME is developed by the group of Prof. Gfeller at
the University of Lausanne, Department of Oncology,
Ludwig Institute for Cancer Research.
For questions, please refer to the FAQ.
Scientific contact: david.gfeller [ at ] unil.ch
Citation:
Gfeller et al. Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes. Cell Systems, 2023.
For questions, please refer to the FAQ.
Scientific contact: david.gfeller [ at ] unil.ch
Citation:
Gfeller et al. Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes. Cell Systems, 2023.
PRIME can be used freely by academic groups
for non-commercial purposes (see license.pdf).
The product is provided free of charge, and, therefore, on an
"as is" basis, without warranty of any kind.
FOR-PROFIT USERS:
If you plan to use PRIME in any for-profit application, you are
required to obtain a separate license.
To do so, please contact Nadette Bulgin (nbulgin [at] lcr.org) at the Ludwig Institute for Cancer Research Ltd.
